Author

J. A. Mueller

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Research Focus:host-pathogen & immune response· 6 Organism:human· 5 Research Focus:drug response / drug discovery· 1 Assay:organoid / primary culture· 1 Assay:proteomics· 1

Frequent Co-Authors

C. Conzelmann· 7 shared J. Muench· 7 shared R. Gross· 6 shared S. Stenger· 6 shared A. Kleger· 3 shared D. Schuetz· 3 shared F. Kirchhoff· 3 shared F. Zech· 3 shared

Activity by Year

2020-2020 · peak 7/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersMicrobiology

C. Conzelmann

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Antiviral activity of plant juices and green tea against SARS-CoV-2 and influenza virus in vitro

B. Frank, C. Conzelmann, T. Weil, R. Gross, P. Jungke, M. Eggers, J. A. Mueller, J. Muench, U. Kessler

This study evaluates the antiviral effects of plant juices and green tea against SARS-CoV-2 and influenza virus in vitro, finding that chokeberry juice inactivates SARS-CoV-2 and influenza virus, while other products show limited efficacy.

bioRxiv · Oct 30, 2020Microbiology

Imperfect innate immune antagonism renders SARS-CoV-2 vulnerable towards IFN-γ and -{lambda}

M. Hayn, M. Hirschenberger, L. Koepke, J. H. Straub, R. Nchioua, M. H. Christensen, S. Klute, C. Prelli Bozzo, W. Aftab, F. Zech, C. Conzelmann, J. A. Mueller, S. Srinivasachar Badarinarayan, C. M. Stuerzel, I. Forne, , K. M. J. Sparrer

This study identifies SARS-CoV-2's vulnerability to IFN-γ and -λ due to its inefficient antagonism of type I and II IFN responses, suggesting potential therapeutic strategies.

bioRxiv · Oct 15, 2020Microbiology

An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection

C. Conzelmann, A. Gilg, R. Gross, D. Schuetz, N. Preising, L. Staendker, B. Jahrsdoerfer, H. Schrezenmeier, K. M. Sparrer, T. Stamminger, S. Stenger, J. Muench, J. A. Mueller

This paper introduces an enzyme-based immunodetection assay to quantify SARS-CoV-2 infection by measuring viral spike protein expression in cell cultures.

Antiviral Research · Sep 1, 2020Peer-reviewedMicrobiology

IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition

C. Prelli Bozzo, R. Nchioua, M. Volcic, J. Krueger, S. Heller, C. M. Stuerzel, D. Kmiec, C. Conzelmann, J. A. Mueller, F. Zech, D. Schuetz, L. Koepke, E. Braun, R. Gross, L. Wettstein, , F. Kirchhoff

This study shows that IFITM proteins are required for SARS-CoV-2 infection and can be targeted to inhibit viral entry and replication.

bioRxiv · Aug 18, 2020 · PreprintMicrobiology

Alpha-1 antitrypsin inhibits SARS-CoV-2 infection

L. Wettstein, C. Conzelmann, J. A. Mueller, T. Weil, R. Gross, M. Hirschenberger, A. Seidel, S. Klute, c. Prelli-Bozzo, F. Zech, N. Preising, G. Fois, R. Lochbaum, P. Knaff, V. Mailaender, , J. Muench

The paper identifies 1-antitrypsin as a specific inhibitor of SARS-CoV-2, showing it blocks viral infection of human airway epithelium at physiological concentrations.

bioRxiv · Jul 2, 2020 · PreprintMicrobiology

Holder Pasteurization Inactivates SARS-CoV-2 in Human Breast Milk

C. Conzelmann, R. Gross, T. L. Meister, D. Todt, A. Krawczyk, U. Dittmer, S. Stenger, J. Muench, E. Steinmann, J. A. Mueller, S. Pfaender

This study shows that Holder pasteurization inactivates SARS-CoV-2 in human breast milk, offering a safe method for infected mothers to breastfeed.

bioRxiv · Jun 17, 2020 · PreprintMicrobiology

Remdesivir but not famotidine inhibits SARS-CoV-2 replication in human pluripotent stem cell-derived intestinal organoids

J. Krueger, R. Gross, C. Conzelmann, J. A. Mueller, L. Koepke, K. Sparrer, D. Schuetz, T. Seufferlein, T. F. E. Barth, S. Stenger, S. Heller, A. Kleger, J. Muench

This study uses human intestinal organoids to show that remdesivir inhibits SARS-CoV-2 replication, while famotidine does not.

bioRxiv · Jun 10, 2020 · PreprintMicrobiology